Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393816 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2KMT2ALMNACYP19A1L3MBTL1 | |
| SCHEMBL538524 | 0.84 | CYP19A1 (0.76) | SMN1; SMN2KMT2ACYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL28634007 | 0.83 | KMT2A (0.59) | SMN1; SMN2KMT2ACYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL4618083 | 0.83 | CYP19A1 (0.65) | SMN1; SMN2KMT2ACYP19A1L3MBTL1TSHR | |
| SCHEMBL789755 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2KMT2ALMNACYP19A1L3MBTL1 | |
| Acetic Acid SCHEMBL28237236 | 0.82 | CYP19A1 (0.69) | SMN1; SMN2KMT2ACYP19A1L3MBTL1GAA | |
| SCHEMBL11759023 | 0.82 | CYP19A1 (0.73) | SMN1; SMN2KMT2ACYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL28795788 | 0.82 | CYP19A1 (0.73) | SMN1; SMN2KMT2ACYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL11131614 | 0.82 | CYP19A1 (0.73) | SMN1; SMN2KMT2ACYP19A1L3MBTL1ALDH1A1 | |
| SCHEMBL8365863 | 0.82 | CYP19A1 (0.73) | SMN1; SMN2KMT2ACYP19A1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110891615-B | System and method for selecting and releasing fragrance | 阿甘香气及精细化学有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114007734-A | Method for preparing capsules | 宝洁公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113660926-A | Capsule | 宝洁公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113631695-A | Capsule | 宝洁公司 | 2021-11-09 | — | — | CN | disclosed |
| US-9890351-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2018-02-13 | — | — | US | disclosed |
| CN-106999972-A | System and method for discharging fragrance | 阿甘芳香和精细化工有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-2741731-B1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2017-05-17 | — | — | EP | disclosed |
| US-8889614-B2 | Encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2741731-A1 | ENCAPSULATES | The Procter and Gamble Company (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2468239-B1 | Encapsulates | PROCTER & GAMBLE INTERNAT OPERATIONS SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130039962-A1 | ENCAPSULATES | ENCAPSYS, LLC | 2013-02-14 | — | — | US | disclosed |
| WO-2013022949-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2013-02-14 | — | — | WO | disclosed |
| CN-102858940-A | Delivery particles | PROCTER & GAMBLE | 2013-01-02 | — | — | CN | disclosed |
| WO-2012085864-A1 | ENCAPSULATES | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) | 2012-06-28 | — | — | WO | disclosed |
| EP-2468239-A1 | Encapsulates | Procter & Gamble International Operations SA (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20120152268-A1 | ENCAPSULATES | PROCTER & GAMBLE COMPANY, THE | 2012-06-21 | — | — | US | disclosed |
| US-20110105378-A1 | ENCAPSULATES | SMETS JOHAN | 2011-05-05 | — | — | US | disclosed |
| US-20110098209-A1 | ENCAPSULATES | SMETS JOHAN | 2011-04-28 | — | — | US | disclosed |
| US-20100190673-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY | 2010-07-29 | — | — | US | disclosed |
| US-20100190674-A1 | ENCAPSULATES | PROCTER & GAMBLE COMPANY, THE | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039962-A1 | ENCAPSULATES | ABCB4, PPIB, FLNB | SMN1; SMN2 3139/4885KMT2A 4084/4885LMNA 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.